Cargando…

Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease

The need for reliable biomarkers for distinguishing Crohn disease (CD) from ulcerative colitis (UC) is increasing. This study aimed at evaluating the diagnostic potential of anti-GP2 antibodies as a biomarker in Chinese patients with CD. In addition, a variety of autoantibodies, including anti-sacch...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shulan, Wu, Ziyan, Luo, Jing, Ding, Xuefeng, Hu, Chaojun, Li, Ping, Deng, Chuiwen, Zhang, Fengchun, Qian, Jiaming, Li, Yongzhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620836/
https://www.ncbi.nlm.nih.gov/pubmed/26496271
http://dx.doi.org/10.1097/MD.0000000000001654
_version_ 1782397365737488384
author Zhang, Shulan
Wu, Ziyan
Luo, Jing
Ding, Xuefeng
Hu, Chaojun
Li, Ping
Deng, Chuiwen
Zhang, Fengchun
Qian, Jiaming
Li, Yongzhe
author_facet Zhang, Shulan
Wu, Ziyan
Luo, Jing
Ding, Xuefeng
Hu, Chaojun
Li, Ping
Deng, Chuiwen
Zhang, Fengchun
Qian, Jiaming
Li, Yongzhe
author_sort Zhang, Shulan
collection PubMed
description The need for reliable biomarkers for distinguishing Crohn disease (CD) from ulcerative colitis (UC) is increasing. This study aimed at evaluating the diagnostic potential of anti-GP2 antibodies as a biomarker in Chinese patients with CD. In addition, a variety of autoantibodies, including anti-saccharomyces cerevisiae antibodies (ASCA), perinuclear anti-neutrophil cytoplasmic antibodies (PANCA), anti-intestinal goblet cell autoantibodies (GAB), and anti-pancreatic autoantibodies (PAB), were evaluated. A total of 91 subjects were prospectively enrolled in this study, including 35 patients with CD, 35 patients with UC, 13 patients with non-IBD gastrointestinal diseases as disease controls (non-IBD DC), and 8 healthy controls (HC). The diagnosis of IBD was determined based on the Lennard-Jones criteria, and the clinical phenotypes of the IBD patients were determined based on the Montreal Classification. Anti-GP2 IgG antibodies were significantly elevated in patients with CD, compared with patients with UC (P = 0.0038), HC (P = 0.0055), and non-IBD DC (P = 0.0063). The prevalence of anti-GP2 IgG, anti-GP2 IgA and anti-GP2 IgA, or IgG antibodies in patients with CD was 40.0%, 37.1%, and 54.3%, respectively, which were higher than those in non-IBD DC (anti-GP2 IgG, 15.4%; anti-GP2 IgA, 7.7%; and anti-GP2 IgA or IgG, 23.1%) and those in patients with UC (anti-GP2 IgG, 11.4%; anti-GP2 IgA, 2.9%; and anti-GP2 IgA or IgG, 14.3%). For distinguishing CD from UC, the sensitivity, specificity, positive predictive value (PPV) and positive likelihood ratios (LR+) were 40%, 88.6%, 77.8%, and 3.51 for anti-GP2 IgG, 37.1%, 97.1%, 92.9%, and 13.0 for anti-GP2 IgA, and 54.3%, 85.3%, 79.2%, and 3.69 for anti-GP2 IgA or IgG. For CD diagnosis, the combination of anti-GP2 antibodies with ASCA IgA increased the sensitivity to 68.6% with moderate loss of specificity to 74.3%. Spearman's rank of order revealed a significantly positive correlation of anti-GP2 IgG with ileocolonic location of disease (L3) (P = 0.043) and a negative correlation of anti-GP2 IgA with biologic therapy (P = 0.012). Our findings suggest that anti-GP2 antibodies could serve as a biomarker for distinguishing patients with CD from patients with UC, and the combination of anti-GP2 antibodies with ASCA IgA may improve the predictive power.
format Online
Article
Text
id pubmed-4620836
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-46208362015-10-27 Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease Zhang, Shulan Wu, Ziyan Luo, Jing Ding, Xuefeng Hu, Chaojun Li, Ping Deng, Chuiwen Zhang, Fengchun Qian, Jiaming Li, Yongzhe Medicine (Baltimore) 3600 The need for reliable biomarkers for distinguishing Crohn disease (CD) from ulcerative colitis (UC) is increasing. This study aimed at evaluating the diagnostic potential of anti-GP2 antibodies as a biomarker in Chinese patients with CD. In addition, a variety of autoantibodies, including anti-saccharomyces cerevisiae antibodies (ASCA), perinuclear anti-neutrophil cytoplasmic antibodies (PANCA), anti-intestinal goblet cell autoantibodies (GAB), and anti-pancreatic autoantibodies (PAB), were evaluated. A total of 91 subjects were prospectively enrolled in this study, including 35 patients with CD, 35 patients with UC, 13 patients with non-IBD gastrointestinal diseases as disease controls (non-IBD DC), and 8 healthy controls (HC). The diagnosis of IBD was determined based on the Lennard-Jones criteria, and the clinical phenotypes of the IBD patients were determined based on the Montreal Classification. Anti-GP2 IgG antibodies were significantly elevated in patients with CD, compared with patients with UC (P = 0.0038), HC (P = 0.0055), and non-IBD DC (P = 0.0063). The prevalence of anti-GP2 IgG, anti-GP2 IgA and anti-GP2 IgA, or IgG antibodies in patients with CD was 40.0%, 37.1%, and 54.3%, respectively, which were higher than those in non-IBD DC (anti-GP2 IgG, 15.4%; anti-GP2 IgA, 7.7%; and anti-GP2 IgA or IgG, 23.1%) and those in patients with UC (anti-GP2 IgG, 11.4%; anti-GP2 IgA, 2.9%; and anti-GP2 IgA or IgG, 14.3%). For distinguishing CD from UC, the sensitivity, specificity, positive predictive value (PPV) and positive likelihood ratios (LR+) were 40%, 88.6%, 77.8%, and 3.51 for anti-GP2 IgG, 37.1%, 97.1%, 92.9%, and 13.0 for anti-GP2 IgA, and 54.3%, 85.3%, 79.2%, and 3.69 for anti-GP2 IgA or IgG. For CD diagnosis, the combination of anti-GP2 antibodies with ASCA IgA increased the sensitivity to 68.6% with moderate loss of specificity to 74.3%. Spearman's rank of order revealed a significantly positive correlation of anti-GP2 IgG with ileocolonic location of disease (L3) (P = 0.043) and a negative correlation of anti-GP2 IgA with biologic therapy (P = 0.012). Our findings suggest that anti-GP2 antibodies could serve as a biomarker for distinguishing patients with CD from patients with UC, and the combination of anti-GP2 antibodies with ASCA IgA may improve the predictive power. Wolters Kluwer Health 2015-10-23 /pmc/articles/PMC4620836/ /pubmed/26496271 http://dx.doi.org/10.1097/MD.0000000000001654 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 3600
Zhang, Shulan
Wu, Ziyan
Luo, Jing
Ding, Xuefeng
Hu, Chaojun
Li, Ping
Deng, Chuiwen
Zhang, Fengchun
Qian, Jiaming
Li, Yongzhe
Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease
title Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease
title_full Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease
title_fullStr Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease
title_full_unstemmed Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease
title_short Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease
title_sort diagnostic potential of zymogen granule glycoprotein 2 antibodies as serologic biomarkers in chinese patients with crohn disease
topic 3600
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620836/
https://www.ncbi.nlm.nih.gov/pubmed/26496271
http://dx.doi.org/10.1097/MD.0000000000001654
work_keys_str_mv AT zhangshulan diagnosticpotentialofzymogengranuleglycoprotein2antibodiesasserologicbiomarkersinchinesepatientswithcrohndisease
AT wuziyan diagnosticpotentialofzymogengranuleglycoprotein2antibodiesasserologicbiomarkersinchinesepatientswithcrohndisease
AT luojing diagnosticpotentialofzymogengranuleglycoprotein2antibodiesasserologicbiomarkersinchinesepatientswithcrohndisease
AT dingxuefeng diagnosticpotentialofzymogengranuleglycoprotein2antibodiesasserologicbiomarkersinchinesepatientswithcrohndisease
AT huchaojun diagnosticpotentialofzymogengranuleglycoprotein2antibodiesasserologicbiomarkersinchinesepatientswithcrohndisease
AT liping diagnosticpotentialofzymogengranuleglycoprotein2antibodiesasserologicbiomarkersinchinesepatientswithcrohndisease
AT dengchuiwen diagnosticpotentialofzymogengranuleglycoprotein2antibodiesasserologicbiomarkersinchinesepatientswithcrohndisease
AT zhangfengchun diagnosticpotentialofzymogengranuleglycoprotein2antibodiesasserologicbiomarkersinchinesepatientswithcrohndisease
AT qianjiaming diagnosticpotentialofzymogengranuleglycoprotein2antibodiesasserologicbiomarkersinchinesepatientswithcrohndisease
AT liyongzhe diagnosticpotentialofzymogengranuleglycoprotein2antibodiesasserologicbiomarkersinchinesepatientswithcrohndisease